10x Genomics
About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Employees: 1,259
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
69% more call options, than puts
Call options by funds: $4.01M | Put options by funds: $2.37M
45% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 76
2.69% less ownership
Funds ownership: 102.42% [Q1] → 99.73% (-2.69%) [Q2]
10% less funds holding
Funds holding: 284 [Q1] → 257 (-27) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]
42% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 64
49% less capital invested
Capital invested by funds: $4.04B [Q1] → $2.05B (-$2B) [Q2]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Barclays Luke Sergott 50% 1-year accuracy 24 / 48 met price target | 41%upside $21 | Overweight Maintained | 15 Oct 2024 |
Stephens & Co. Mason Carrico 73% 1-year accuracy 16 / 22 met price target | 102%upside $30 | Overweight Reiterated | 10 Oct 2024 |
Canaccord Genuity Kyle Mikson 73% 1-year accuracy 11 / 15 met price target | 35%upside $20 | Buy Maintained | 10 Oct 2024 |
Stephens & Co. Mason Carrico 73% 1-year accuracy 16 / 22 met price target | 102%upside $30 | Overweight Reiterated | 4 Sept 2024 |
Leerink Partners Mike Kratky 50% 1-year accuracy 2 / 4 met price target | 136%upside $35 | Outperform Initiated | 3 Sept 2024 |
Financial journalist opinion
Based on 6 articles about TXG published over the past 30 days